Recombinant protective antigen 102 (rPA102): profile of a second-generation anthrax vaccine

Author: Keitel, Wendy A

Source: Expert Review of Vaccines, Volume 5, Number 4, August 2006 , pp. 417-430(14)

Publisher: Expert Reviews

Key:

- Free Content

- New Content

- Subscribed Content

- Free Trial Content

Abstract:

Recent terrorist attacks involving the use of Bacillus anthracis spores have stimulated interest in the development of new vaccines for anthrax prevention. Studies of the pathogenesis of anthrax and of the immune responses following infection and immunization underscore the pivotal role that antibodies to the protective antigen play in protection. The most promising vaccine candidates contain purified recombinant protective antigen. Clinical trials of one of these, recombinant protective antigen (rPA)102, are underway. Initial results suggest that rPA102 is well tollerated and immunogenic. Additional trials are necessary to identify optimal formulations and immunization regimens for pre- and postexposure prophylaxis. Future licensure of these and other candidate vaccines will depend on their safety and immunogenicity profiles in humans, and their ability to confer protection in animal models of inhalational anthrax.

Keywords: anthrax; anthrax vaccine; Bacillus anthracis; immunization; recombinant protective antigen

Document Type: Research article

DOI: 10.1586/14760584.5.4.417

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$73.00 plus tax Refund Policy